Management of patients with intermittent claudication and chronic critical limb ischaemia (CLI)
should take into account the general prognosis as well as progression of the disease. Reducing the known risk factors for the development of atherosclerosis is still the mainstay of therapy in claudicants. They should refrain from smoking, follow an appropriate diet and have hypertension and diabetes tightly controlled. The same is true for patients with CLI but is not enough for the most serious phase of peripheral arterial obstructive disease (PAOD). What then is the place of drugs in the primary medical care of patients with a limbthreatening condition such as CLI? There is a theoretical rationale for induced hypertension, hyperbaric oxygen, heparin, systemic or regional thrombolysis, defibrinogenation, haemodilution, vasoactive drugs, lumbar sympathetic block and epidural spinal cord stimulation. Published studies of such agents have been reviewed.t? From a strict scientific point of view it is however not proven that any of the drugs or methods mentioned above is effective in the severe clinical condition of CLI as defined in the Consensus Document.
Based on case reports, continuous intra-arterial infusion with PGE 1 suggested some benefit might be obtained for patients with severe peripheral © Edward Arnold 1994 arterial disease, and intravenous infusions sometimes promoted healing of ischaemic ulcers-but most of these trials lacked a placebo or reference drug. A critical review of randomized, open or double-blind trials comparing intra-arterial or intravenous intermittent infusions of PGE 1 or iloprost, a prostacyclin analogue with placebo, pentoxifylline or adenosine triphosphate (ATP) was given in the Consensus Document.s
There are seven published randomized clinical trials conducted in a double-blind manner for a short duration (three to four days) comparing the intra-arterial and intravenous infusion of PGE 1 or PGE 2 with placebo in at least 20 patients with severe arterial disease (Fontaine stages 3 and 4).5-11 Only two trials, with PGI 2 administered intra-arteriallys or intravenously.u gave a significant reduction in ulcer size> or pain.!! In retrospect, it is improbable that treatment lasting only 72 hours could have shown efficacy in such a chronic condition.
Using the same methodological selection criteria as noted above for short-term trials, there are eleven published trials evaluating the effect of PGE 1 or iloprost administered intermittently either by intra-arterial or intravenous infusions, but for at least two weeks and up to six weeks. [12] [13] [14] [15] [16] [17] [18] [19] [20] The first controlled double-blind study with PGE 1 over a longer period was conducted in 65 patients with ischaemic ulcers in whom reconstructive vascular surgery was either not feasible or had failed: however, 74% of the selected patients had thromboangiitis obliterans.P A high-dose (0.15 ng/kg/min, n = 22) intra-arterial perfusion of PGE 1 for an average of 24 days resulted in a significantly higher (p < 0.04) clinical response rate than did low-dose PGE 1 (0.05 ng/kg/min, n = 25) or oral inositol nicotinate (6 x 200 mg daily, n = 18). In two of the series of eleven trials intermittent intra-arterial infusions of PGE 1 were compared with adenosine triphosphate (ATP): significantly better results were achieved in PGE 1 in ulcer healing, rest pain and consumption of analgesics. 16 While in the ATP group amputation was necessary in 35% of patients, only 10% of the patients treated with PGE 1 required amputation (p < 0.05). In another comparative trial, intra-arterial PGE 1 also achieved better results than ATP.13 After a treatment of 23 days, on average, 39% of patients in the PGE 1 group remitted to stage II, as compared to 19% in the ATP group: however, there was no significant intergroup difference in the reduction of ulcer size. In a comparative study of intravenous intermittent infusions of PGE 1 versus pentoxifyline,13 82% of the patients in the PGE 1 group showed complete or partial ulcer healing but only 51 % in the pentoxifylline group (p < 0.02). At six months follow-up the leg condition had deteriorated so much that an amputation was needed in 17% of the patients treated with PGE 1 and in 34% in the pentoxifylline group.
Among the eleven trials administering prostanoids in intermittent infusions for at least two weeks, six were performed with iloprost versus placebo,17-22 All but two 19 • 20 showed a significant reduction in ulcer size or score (area depth, base and edge of ulcers) by the end of the infusion period with iloprost in comparison with placebo. Although the definition and measurement of ulcer healing were imprecise and varied from study to study, it can be claimed with reasonable certainty that skin defects showed evidence of healing in patients treated with iloprost and reached a statistical significance in four of the six studies. There was no formal follow-up in the three German trials with i1oprost versus placebo17.18.20 and follow-up is missing in 44% of the patients in the French trial.s! In contrast, the Swedisht? and the UK22 trials have a good follow-up at six months and the rate difference in major amputation and death were 17.4% and 14% in favour of iloprost, with a total of 37 amputations or deaths out of 97 patients in the two iloprost groups compared to 55 out of 101 patients in the two standard treatment groups.
In conclusion, there is convincing evidence that prostanoids (PGE t , iloprost) given by intermittent intravenous daily infusions for at least two weeks reduces rest pain, improves ulcer healing and appears to decrease the amputation above ankle level at six month follow-up in patients with chronic critical limb ischaemia.
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